A U.S. government regulator's positive review of an anti-clotting drug made
from the milk of a genetically modified goat has sparked consumer-group concerns
"The regulatory process seems to have put the cart before the horse, analyzing
the safety of the product before it has opined on the safety of the
manufacturing process,"
Greg Jaffe of
the Center for Science in the Public Interest said.
The U.S.
Food and
Drug Administration "clearly needs to impose cradle-to-grave conditions to
prevent the goats from leaving the farm or their products from entering the food
supply," Jaffee told USA Today.
ATryn is produced by GTC Biotherapeutics Inc. (NASDAQ:GTCB) of Framingham, Mass., for use in people with a hereditary lack of the protein antithrombin, which makes them vulnerable to life-threatening blood clots. The drug would be used during surgery and childbirth.
clipped from: www.upi.com